Mr. Moch joined Cognition Therapeutics in October 2016 as president and chief executive officer. He has broad expertise building, financing and leading private and public life science companies from start-up through commercialization, having previously served as president and CEO of four life science companies: Chimerix, Inc., an antiviral therapeutics company; BioMedical Enterprises (acquired by DePuy, a Johnson & Johnson company), a manufacturer and marketer of nitinol orthopedic implants; Alteon, Inc., a developer of small molecule therapeutics for cardiovascular aging and diabetic complications; and Biocyte Corporation, where he pioneered the storage and therapeutic use of cord blood stem cells and launched the first cord blood stem cell storage bank.

Mr. Moch started his career in biotech drug development as a co-founder and vice president of The Liposome Company, Inc. (acquired by Elan Corporation), a pioneer in the use of liposomes for the delivery of anticancer and antifungal drugs. He has also been a managing partner of The Salutramed Group, LLC, a managing director of Healthcare Investment Banking at ThinkEquity Partners and a management consultant with McKinsey & Company, Inc.

Dr. Rishton is a co-founder and the inventor of the proprietary conditioned extraction chemical library at Cognition Therapeutics. He has widespread pharma drug discovery experience and has led drug discovery programs across multiple therapeutic areas for over 20 years. He has leveraged this experience to develop medicinal chemistry scaffolds instrumental in identifying sigma-2/PGRMC1 as a pharmacologically attractive Alzheimer’s drug target.

Dr. Rishton was the founding medicinal chemist at Amgen’s Thousand Oaks site and was responsible for much of the program initiation and group building for the Amgen Small Molecule Drug Discovery Group. He led the medicinal chemistry program for Amgen’s Secretase Team, among the first to produce small molecule secretase inhibitors as potential therapeutic agents for Alzheimer’s disease. He was also the chemistry manager for Amgen’s Sensipar pre-clinical and clinical development programs which spanned seven years and involved all facets of development including PKDM profiling, formulation, manufacturing, and human clinical trials resulting in the commercial launch of Amgen’s first oral small molecule product, Sensipar. Later, Dr. Rishton retired from Amgen to continue his efforts toward Alzheimer’s disease drug development as founder and director of the nonprofit Channel Islands Alzheimer’s Institute.

Dr. Catalano is the founder of Cognition Therapeutics and architect of its proprietary and unique biological discovery platform that is based on unbiased phenotypic screens in the target cell population of mature primary neurons. Using her 15 years of industry experience, she and her team discovered and developed the company’s drug candidate Elayta (CT1812), currently in clinical testing for the treatment of patients with mild-to-moderate Alzheimer’s disease.

Prior to founding Cognition Therapeutics, Dr. Catalano was director of discovery biology for Acumen Pharmaceuticals, leading the team that discovered Acumen’s lead candidates targeting Aβ oligomers. Earlier at Rigel, she led the team that pioneered the use of high content phenotypic screening to discover the Aurora kinase inhibitor R763. In scientific leadership roles within the neurophysiology and neuroimaging groups at Roche Palo Alto she led exploratory programs against targets involved in anxiety, depression and schizophrenia.

Dr. Catalano received her Ph.D. from U.C. Irvine and postdoctoral training at U.C. Berkeley with Dr. Carla Shatz and at Caltech with Drs. Mary Kennedy and Scott Fraser studying the neurobiology of synaptic plasticity.

Dr. Grundman joined Cognition Therapeutics to provide leadership for their clinical strategy and product development. He has over 25 years’ experience in clinical research in CNS disorders. He is president and CEO of Global R&D Partners, LLC, a consulting firm that advises pharmaceutical and biotechnology companies on development of novel agents for the diagnosis and treatment of serious and life-threatening diseases. Dr. Grundman also currently serves as professor of neurosciences at the University of California San Diego (UCSD) and previously he held positions at both Janssen Alzheimer Immunotherapy Research & Development, LLC and Elan Pharmaceuticals as vice president of clinical development, where he led the clinical immunotherapy trials for Alzheimer’s disease.

Prior to joining industry, Dr. Grundman was associate director of the Alzheimer’s Disease Cooperative Study (ADCS) at the University of California, San Diego (UCSD). He is an inventor on a number of patents related to Alzheimer’s disease therapy and has served on the FDA Peripheral and Central Nervous System Advisory Committee.

He received his B.A. in biochemistry from New York University, his M.D. and neurology training at the Albert Einstein College of Medicine and a Master of Public Health degree from Columbia University.

Dr. Safferstein joined Cognition Therapeutics as CEO when the Company established operations in Pittsburgh in 2007. From then until October 2016 he served in this role and was responsible for raising several rounds of financing from Angel investors and other financial institutions enabling Cognition Therapeutics to progress its drug discovery and development efforts to the clinical stage.

Prior to this, Dr. Safferstein served as vice president of business development at Omrix Biopharmaceuticals, a commercial-stage biosurgical and passive immunotherapy company. He has also held the roles of executive vice president of corporate development for TransPharma Medical, vice president of business development for Acorda Therapeutics and has served in various business development and marketing positions within Bristol-Myers Squibb. From 1991-1997, Dr. Safferstein was director of Technology Transfer at the National Heart, Lung and Blood Institute and cooperative venture manager for the National Institute of Allergy and Infectious Diseases, National Institutes of Health.

Dr. Safferstein received his B.A. in biochemistry from Rutgers University, a Ph.D. in human anatomy and neurobiology from the University of Louisville, a J.D. from the American University, Washington College of Law and an M.B.A. from Columbia University.

Mr. DiPalma is a managing director at Danforth Advisors, LLC, where he has served since April 2014. He brings more than 25 years of experience in providing life sciences and healthcare, which includes founding two start-ups, working with venture-backed companies, subsidiaries of Fortune 100 firms and publicly traded companies. His core strengths include operational management, strategic planning and corporate and business development, fundraising, and mergers and acquisitions.

Previously, Mr. DiPalma served as the CFO of two public companies, and as CFO, COO, CEO or director of eight privately held companies. In these roles, he has managed finance, accounting, corporate communications, human resources, information technology, facilities, business development and manufacturing functions. He participated in the successful reorganization of Cambridge Biotech from Chapter 11 bankruptcy protection into Aquila BioPharmaceuticals, and led the effort to take RXi public. Mr. DiPalma received his B.S. from the University of Massachusetts-Lowell and his M.B.A. from Babson College.